Cherry J D, Connor J D, McIntosh K, Benenson A S, Alling D W, Rolfe U T, Schanberger J E, Mattheis M J
J Infect Dis. 1977 Jan;135(1):176-82. doi: 10.1093/infdis/135.1.176.
Six months after subcutaneous vaccination with one of four smallpox vaccines, 655 children were challenged with a standard percutaneous smallpox vaccine. Response to reimmunization was characterized by a significant acceleration and diminution of skin response, but not to the degree seen in an equivalent group who had received their primary immunization percutaneously. Fever after revaccination was absent if there had been a "take" with primary subcutaneous vaccination. The overall incidence of minor vaccine-related complications with revaccination was 2-1/2%. The neutralizing antibody response to revaccination was markedly reduced, as compared to that of children who received either one or two successful percutaneous vaccinations. Subcutaneous vaccination followed by percutaneous vaccination is not recommended as a schedule for smallpox immunization, because complications are not avoided, and the incidence and mean titer of resultant neutralizing antibody are low.
在用四种天花疫苗之一进行皮下接种六个月后，655名儿童接受了标准的经皮天花疫苗激发接种。再次免疫的反应表现为皮肤反应显著加速和减弱，但程度不如同等组中经皮接受初次免疫的儿童。如果初次皮下接种成功“接种”，再次接种后则不会发烧。再次接种后与疫苗相关的轻微并发症的总体发生率为2.5%。与接受一次或两次成功经皮接种的儿童相比，再次接种后的中和抗体反应明显降低。不建议将皮下接种后再进行经皮接种作为天花免疫程序，因为无法避免并发症，而且产生的中和抗体的发生率和平均滴度都很低。
